Agio Pharmaceuticals Inc. (NASDAQ: AGIO) saw its shares sink on Monday after the firm announced results from its midstage trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). Unfortunately, results did not live up to expectations.
Specifically, the firm reported results from its Phase 1/2 study evaluating investigational oral IDHIFA (enasidenib). IDHIFA is in development in collaboration with Celgene Corp. (NASDAQ: CELG).
Data in an oral session at the 22nd Congress of the European Hematology Association (EHA) demonstrated an overall response rate of 37%, including a complete response rate of 20.1% in 214 patients with R/R AML who received enasidenib.
Unfortunately, a maximum tolerated dose was not reached. Although, the overall safety profile observed for enasidenib was consistent with previously reported data. The most common treatment-emergent adverse effects were nausea (48%), diarrhea (41%), fatigue (41%), decreased appetite (34%) and blood bilirubin increased (33%). For all patients in the study, 26.1% had treatment-related serious adverse events, notably IDH differentiation syndrome (7%), leukocytosis (4%), tumor lysis syndrome (3%) and hyperbilirubinemia (2%).
Chris Bowden, M.D., chief medical officer of Agios, commented:
With data from an additional 105 patients and the first look at data from the Phase 2 expansion in R/R AML patients treated at the recommended Phase 2 starting dose of 100 mg once daily, these updated results underscore the consistency and durability of response for enasidenib as a potential first-in-class therapy for patients with relapsed or refractory AML and an IDH2 mutation. We are working with our partner Celgene to quickly bring this oral, targeted therapy to patients with limited treatment options.
Shares of Agio were trading down about 10% at $53.20 on Monday, with a consensus analyst price target of $61.89 and a 52-week range of $35.84 to $67.74.
Celgene was down about 0.7% at $133.33, with a consensus price target of $142.04 and a 52-week trading range of $94.42 to $135.18.
Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.